Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, NanoxelTM
- 568 Downloads
An increasing research interest has been directed toward nanoparticle-based drug delivery systems for their advantages. The appropriate amalgamation of pH sensitivity and tumor targeting is a promising strategy to fabricate drug delivery systems with high efficiency, high selectivity and low toxicity.
Materials and Methods
A novel pH sensitive Cremophor-free paclitaxel formulation, NanoxelTM, was developed in which the drug is delivered as nanomicelles using a polymeric carrier that specifically targets tumors. The efficiency and mechanism of intracellular paclitaxel delivery by NanoxelTM was compared with two other commercially available paclitaxel formulations: AbraxaneTM and IntaxelTM, using different cell lines representing target cancers [breast, ovary and non-small cell lung carcinoma (NSCLC)] by transmission electron microscopy and quantitative intracellular paclitaxel measurements by high performance liquid chromatography.
The data obtained from the present study revealed that the uptake of nanoparticle-based formulations NanoxelTM and AbraxaneTM is mediated by the process of endocytosis and the uptake of paclitaxel was remarkably superior to IntaxelTM in all cell lines tested. Moreover, the intracellular uptake of paclitaxel in NanoxelTM- and AbraxaneTM-treated groups was comparable. Hence, the nanoparticle-based formulations of paclitaxel (NanoxelTM and AbraxaneTM) are endowed with higher efficiency to deliver the drug to target cells as compared to the conventional Cremophor-based formulation.
NanoxelTM appears to be of great promise in tumor targeting and may provide an advantage for paclitaxel delivery into cancer cells.
KeywordsPaclitaxel Delivery system Tumor Naoxel Nanoparticle Intaxel
- 9.Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res Off J Am Assoc Cancer Res 12(4):1317–1324CrossRefGoogle Scholar
- 10.Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A et al (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin Cancer Res 11(11):4136–4143PubMedCrossRefGoogle Scholar
- 12.Feng T, Szabo E, Dziak E, Opas M (2010) Cytoskeletal disassembly and cell rounding promotes adipogenesis from ES cells. Stem Cell Rev 6(1):74–85Google Scholar
- 13.Petrelli F, Borgonovo K, Barni S (2010) Targeted delivery for breast cancer therapy: the history of nanoparticle–albumin-bound paclitaxel. Expert Opin Pharmacother 11(8):1413–1432Google Scholar
- 14.Sun X, Yan Y, Liu S, Cao Q, Yang M, Neamati N, et al (2011) 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy. J Nucl Med 52(1):140–146Google Scholar
- 17.Wang SH, Lee CW, Chiou A, Wei PK (2010) Size-dependent endocytosis of gold nanoparticles studied by three-dimensional mapping of plasmonic scattering images. J Nanobiotechnology 8:33Google Scholar
- 24.Singh AT, Jaggi M, Khattar D, Awasthi A, Mishra SK, Tyagi S et al (2008) A novel nanopolymer based tumor targeted delivery system for paclitaxel. J Clin Oncol 26(May 20 suppl; abstr 11095)Google Scholar